Pure Bioscience Inc
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. Its technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. The comp… Read more
Pure Bioscience Inc (PURE) - Total Liabilities
Latest total liabilities as of January 2025: $4.84 Million USD
Based on the latest financial reports, Pure Bioscience Inc (PURE) has total liabilities worth $4.84 Million USD as of January 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pure Bioscience Inc - Total Liabilities Trend (1996–2024)
This chart illustrates how Pure Bioscience Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pure Bioscience Inc Competitors by Total Liabilities
The table below lists competitors of Pure Bioscience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chia Yi Steel Co Ltd
TWO:2067
|
Taiwan | NT$1.60 Billion |
|
PT Cipta Perdana Lancar Tbk
JK:PART
|
Indonesia | Rp149.04 Billion |
|
CDT Environmental Technology Investment Holdings Limited ordinary shares
NASDAQ:CDTG
|
USA | $9.85 Million |
|
Brisbane Broncos Ltd
AU:BBL
|
Australia | AU$16.80 Million |
|
Cauldron Energy Limited
PINK:CAULF
|
USA | $1.01 Million |
|
Tarena International Inc
NASDAQ:TCTM
|
USA | $1.90 Billion |
Liability Composition Analysis (1996–2024)
This chart breaks down Pure Bioscience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 8.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pure Bioscience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pure Bioscience Inc (1996–2024)
The table below shows the annual total liabilities of Pure Bioscience Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-07-31 | $3.68 Million | +137.09% |
| 2023-07-31 | $1.55 Million | +170.09% |
| 2022-07-31 | $575.00K | -40.72% |
| 2021-07-31 | $970.00K | -35.85% |
| 2020-07-31 | $1.51 Million | +103.77% |
| 2019-07-31 | $742.00K | -42.66% |
| 2018-07-31 | $1.29 Million | -49.04% |
| 2017-07-31 | $2.54 Million | 0.00% |
| 2016-07-31 | $2.54 Million | +189.18% |
| 2015-07-31 | $878.00K | -52.33% |
| 2014-07-31 | $1.84 Million | -39.67% |
| 2013-07-31 | $3.05 Million | -16.13% |
| 2012-07-31 | $3.64 Million | +287.32% |
| 2011-07-31 | $939.78K | +56.83% |
| 2010-07-31 | $599.22K | +2.87% |
| 2009-07-31 | $582.52K | -41.59% |
| 2008-07-31 | $997.26K | +98.51% |
| 2007-07-31 | $502.38K | +21.97% |
| 2006-07-31 | $411.89K | +16.58% |
| 2005-07-31 | $353.30K | -88.41% |
| 2004-07-31 | $3.05 Million | +160.81% |
| 2003-07-31 | $1.17 Million | 0.00% |
| 2002-07-31 | $1.17 Million | +92.55% |
| 2001-07-31 | $606.89K | +9.10% |
| 2000-07-31 | $556.28K | -49.43% |
| 1999-07-31 | $1.10 Million | +22.22% |
| 1998-07-31 | $900.00K | +800.00% |
| 1997-07-31 | $100.00K | -88.89% |
| 1996-07-31 | $900.00K | -- |